作者: J. E. Creamer , J. C. O’Keefe , M. B. Maltz , S. O. Banim
DOI: 10.1007/978-3-642-73010-8_37
关键词:
摘要: A double-blind, placebo-controlled study was performed to assess whether nisoldipine, a new dihydropyridine calcium channel blocker, conferred any additional benefit in patients with chronic stable angina and documented coronary artery disease who were already taking the maximum-tolerated doses of beta-blocking drugs.